ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
ATF5 | Activating transcription factor 5 | Transcription factors
| | | | | Group enriched |
ATP2B3 | ATPase, Ca++ transporting, plasma membrane 3 | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Group enriched |
AUNIP | Aurora kinase A and ninein interacting protein | | | | | | Tissue enhanced |
BAG2 | BCL2-associated athanogene 2 | Plasma proteins
| | | | | Tissue enhanced |
BAI2 | Brain-specific angiogenesis inhibitor 2 | G-protein coupled receptors Predicted membrane proteins Predicted secreted proteins Transporters
| | | | | Tissue enriched |
BARHL2 | BarH-like homeobox 2 | Transcription factors
| | | | | Tissue enriched |
BARX2 | BARX homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
BASP1 | Brain abundant, membrane attached signal protein 1 | Cytoskeleton related proteins Plasma proteins Transporters
| | | | | Tissue enhanced |
BCAN | Brevican | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
BCL2L14 | BCL2-like 14 (apoptosis facilitator) | | | | | | Tissue enhanced |
BHMT | Betaine--homocysteine S-methyltransferase | Enzymes Plasma proteins
| | | | | Group enriched |
BIN1 | Bridging integrator 1 | Disease related genes
| | | | | Tissue enriched |
BLM | Bloom syndrome, RecQ helicase-like | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enriched |
BNC2 | Basonuclin 2 | Transcription factors
| | | | | Tissue enhanced |
BRIP1 | BRCA1 interacting protein C-terminal helicase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BRSK1 | BR serine/threonine kinase 1 | Enzymes Plasma proteins Predicted membrane proteins
| | | | | Tissue enriched |
BSPRY | B-box and SPRY domain containing | | | | | | Tissue enhanced |
BTBD11 | BTB (POZ) domain containing 11 | | | | | | Group enriched |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BTNL8 | Butyrophilin-like 8 | Predicted membrane proteins
| | | | | Group enriched |
BUB1 | BUB1 mitotic checkpoint serine/threonine kinase | Enzymes
| | | | | Tissue enhanced |
BUB1B | BUB1 mitotic checkpoint serine/threonine kinase B | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
C11orf63 | Chromosome 11 open reading frame 63 | | | | | | Tissue enhanced |
C15orf27 | Chromosome 15 open reading frame 27 | Predicted membrane proteins
| | | | | Tissue enhanced |
C16orf46 | Chromosome 16 open reading frame 46 | | | | | | Tissue enhanced |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
C18orf54 | Chromosome 18 open reading frame 54 | Predicted secreted proteins
| | | | | Tissue enhanced |
C19orf80 | Chromosome 19 open reading frame 80 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
C1orf110 | Chromosome 1 open reading frame 110 | | | | | | Tissue enhanced |
C1orf56 | Chromosome 1 open reading frame 56 | Predicted secreted proteins
| | | | | Tissue enriched |
C21orf58 | Chromosome 21 open reading frame 58 | | | | | | Tissue enhanced |
C9 | Complement component 9 | Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
C9orf117 | Chromosome 9 open reading frame 117 | | | | | | Tissue enriched |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CABLES2 | Cdk5 and Abl enzyme substrate 2 | Predicted membrane proteins
| | | | | Tissue enriched |
CABYR | Calcium binding tyrosine-(Y)-phosphorylation regulated | Cytoskeleton related proteins
| | | | | Tissue enriched |
CAGE1 | Cancer antigen 1 | | | | | | Tissue enriched |
CALB1 | Calbindin 1, 28kDa | | | | | | Tissue enriched |
CALB2 | Calbindin 2 | Plasma proteins
| | | | | Tissue enhanced |
CAMK2N2 | Calcium/calmodulin-dependent protein kinase II inhibitor 2 | | | | | | Group enriched |
CAMK4 | Calcium/calmodulin-dependent protein kinase IV | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CAMKK1 | Calcium/calmodulin-dependent protein kinase kinase 1, alpha | Enzymes
| | | | | Tissue enhanced |
CAPN14 | Calpain 14 | Enzymes
| | | | | Tissue enriched |
CAPS | Calcyphosine | | | | | | Tissue enriched |
CASC5 | Cancer susceptibility candidate 5 | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
CBS | Cystathionine-beta-synthase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
CBX2 | Chromobox homolog 2 | Disease related genes
| | | | | Tissue enhanced |